Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib + Pirfenidone Follow-up in Japanese IPF
NCT01417156Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2011
- Primary completion
- Oct 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Started Sep 2011; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01417156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01417156.